- Home
- LTC vs ARVN Comparison
LTC vs ARVN Comparison
Compare LTC & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTC
- ARVN
- Stock Information
- Founded
- LTC 1992
- ARVN 2015
- Country
- LTC United States
- ARVN United States
- Employees
- LTC N/A
- ARVN N/A
- Industry
- LTC Real Estate Investment Trusts
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- LTC Real Estate
- ARVN Health Care
- Exchange
- LTC Nasdaq
- ARVN Nasdaq
- Market Cap
- LTC 1.8B
- ARVN 1.7B
- IPO Year
- LTC 1992
- ARVN 2018
- Fundamental
- Price
- LTC $38.19
- ARVN $22.48
- Analyst Decision
- LTC Hold
- ARVN Strong Buy
- Analyst Count
- LTC 4
- ARVN 13
- Target Price
- LTC $35.75
- ARVN $60.00
- AVG Volume (30 Days)
- LTC 306.5K
- ARVN 657.2K
- Earning Date
- LTC 10-28-2024
- ARVN 10-30-2024
- Dividend Yield
- LTC 5.97%
- ARVN N/A
- EPS Growth
- LTC 20.82
- ARVN N/A
- EPS
- LTC 2.32
- ARVN N/A
- Revenue
- LTC $198,710,000.00
- ARVN $161,100,000.00
- Revenue This Year
- LTC N/A
- ARVN $237.44
- Revenue Next Year
- LTC $0.79
- ARVN N/A
- P/E Ratio
- LTC $16.44
- ARVN N/A
- Revenue Growth
- LTC 4.70
- ARVN 1.07
- 52 Week Low
- LTC $30.30
- ARVN $20.28
- 52 Week High
- LTC $39.89
- ARVN $53.08
- Technical
- Relative Strength Index (RSI)
- LTC 55.29
- ARVN 32.36
- Support Level
- LTC $38.61
- ARVN $24.92
- Resistance Level
- LTC $39.89
- ARVN $28.70
- Average True Range (ATR)
- LTC 1.09
- ARVN 1.55
- MACD
- LTC 0.03
- ARVN -0.48
- Stochastic Oscillator
- LTC 57.29
- ARVN 0.28
About LTC LTC Properties Inc.
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in seniors housing and healthcare facilities through mortgage loans, property lease transactions, and other investments. Its real estate investments includes different types of properties such as Independent living communities, Assisted living communities, Memory care communities, Skilled nursing centers and other types of properties.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.